Campbell's Company (The) vs Kenvue
Side-by-side comparison of AI visibility scores, market position, and capabilities
Camden NJ diversified food company (NYSE: CPB) at $10.3B FY2025 sales; rebranded to The Campbell's Company (Nov 2024), Rao's acquisition $2.7B, new CEO Mick Beekhuizen (Feb 2025) competing with General Mills for shelf-stable meals.
About
The Campbell's Company is a Camden, New Jersey-based diversified food manufacturer — publicly traded on the New York Stock Exchange (NYSE: CPB) as an S&P 500 Consumer Staples component — producing and marketing soups, snacks, sauces, and beverages under iconic consumer brands through approximately 14,000 employees with fiscal year 2025 net sales of $10.3 billion. Founded in 1869 by Joseph Campbell and Abraham Anderson as a fruit and vegetable canning operation, Campbell's became a cultural icon through chemist John T. Dorrance's 1897 condensed soup innovation. The company rebranded from Campbell Soup Company to The Campbell's Company in November 2024 (shareholder-approved) to signal its evolution beyond soup into a diversified food portfolio. Mick Beekhuizen became the 15th CEO in company history on February 1, 2025, succeeding Mark Clouse who retired to become President of the NFL's Washington Commanders. Beekhuizen joined Campbell's in 2019 as CFO and was elevated to President of Meals & Beverages in 2022. The company's $2.7 billion acquisition of Sovos Brands in 2024 added Rao's premium pasta sauce (the highest-rated mass-market pasta sauce brand), Michael Angelo's Italian meals, and noosa yogurt to the portfolio.
Skillman NJ consumer health (NYSE: KVUE) ~$15.5B FY2024 revenue; J&J spinoff May 2023, Tylenol/Band-Aid/Neutrogena/Listerine/Aveeno portfolio, talc litigation exposure competing with Haleon and P&G.
About
Kenvue Inc. is a Skillman, New Jersey-based consumer health company — publicly traded on the New York Stock Exchange (NYSE: KVUE) as an S&P 500 Consumer Staples component — marketing and selling over-the-counter medicines, skin health and beauty products, and essential health products through iconic consumer brands including Tylenol (pain and fever relief), Band-Aid (wound care), Neutrogena (skin care), Johnson's (baby care), Listerine (oral care), Aveeno (skincare), Motrin/Advil (ibuprofen pain relief), Zyrtec (allergy), Nicorette (smoking cessation), Neosporin (antibiotic ointment), and Benadryl through approximately 22,000 employees in 165 countries. Kenvue was separated from Johnson & Johnson through an IPO in May 2023 (the largest US IPO of 2023) and a tax-free distribution of J&J's remaining 89.6% stake to J&J shareholders in August 2023 — creating the world's largest pure-play consumer health company by market capitalization, with J&J retaining no ownership. In fiscal year 2024, Kenvue reported revenues of approximately $15.5 billion, with organic growth facing headwinds from lower cold/cough/flu season severity (Tylenol, Zyrtec, Benadryl volume sensitive to respiratory illness intensity), competitive pressure in skin health (Neutrogena competing with Korean beauty brands, Cerave, and pharmacy private label), and macroeconomic consumer trading down to lower-price alternatives in some markets. CEO Thibaut Mongon leads Kenvue's strategy of investing in the brand superiority of its household name portfolio while improving operational efficiency in the post-spinoff period (implementing Kenvue's own supply chain infrastructure, IT systems, and organizational structure previously shared with J&J).
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.